NATtrol SARS-CoV-2 Variant Panel (4 x 0.5 mL)

(No reviews yet) Write a Review
SKU:
NATSARS(COV2)-VP
Availability:
Usually Shipped in 5 to 7 Working Days
Certification:
RUO
  • NATtrol SARS-CoV-2 Variant Panel NATSARS(COV2)-VP
  • NATtrol SARS-CoV-2 Variant Panel NATSARS(COV2)-VP
  • NATtrol SARS-CoV-2 Variant Panel NATSARS(COV2)-VP
  • NATtrol SARS-CoV-2 Variant Panel NATSARS(COV2)-VP
€410.00
Frequently bought together:

Description

NATtrol™ SARS-CoV-2 Variant Panel NATSARS(COV2)-VP:

1 x 0.5 mL vial Alpha Variant (B.1.1.7)
1 x 0.5 mL vial Beta Variant (B.1.351)
1 x 0.5 mL vial Gamma Variant (P.1)
1 x 0.5 mL vial Delta Variant (B.1.617.2)


Target concentrations - 50,000 cp/mL

PRODUCT DESCRIPTION:

NATtrol™ SARS-CoV-2 Variant Panel is formulated with purified, intact viral particles. The virus particles have been chemically modified to render them non-infectious and refrigerator stable. NATSARS(COV2)-VP contains 4 x 0.5mL vials of viral NATtrol™ as listed in Table 1. The panel members are supplied in a proprietary matrix.

INTENDED USE:

NATtrol™ SARS-CoV-2 Variant Panel is designed to evaluate the performance of nucleic acid tests for determination of the presence of SARS-CoV-2 RNA. NATtrol™ SARS-CoV-2 Variant Panel enables laboratories to monitor test variation, lot-to-lot test kit performance, operator variation, and can provide assistance in identifying random or systemic error.

WARNINGS AND PRECAUTIONS:

• NATtrol™ inactivation was carried out on SARS-CoV-2 stocks used to formulate the product. The inactivation was verified in a standard microbiological growth protocol.
• This product contains inactivated microorganisms and materials of human and animal origin. Safe practices suggest that the controls be considered potentially infectious and to use Universal Precautions when handling.
• Refer to CDC guidelines and local regulations for handling and disposal.
• The matrix used in the manufacture of this product is treated with 0.09% sodium azide. It was manufactured from Human Serum Albumin that has been tested and found to be non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1 and HCV by FDA approved Nucleic Acid Test (NAT) methods.
• Heat inactivated Fetal Bovine Serum used in the manufacture of this product meets applicable USDA requirements for abattoir sourced animals, traceability and country of origin. The materials were collected at USDA licensed establishments or legally imported from countries recognized by the USDA as negligible or controlled for risk for Bovine Spongiform Encephalopathy (BSE) and other exotic disease agents. Donor animals were inspected ante and post mortem at the abattoir as required by the USDA.
• Do not use past the expiration date on the label.
• To avoid cross-contamination, use separate pipette tips for all materials.

RECOMMENDED STORAGE:

NATtrol™ SARS-CoV-2 Variant Panel should be stored at 2-8°C.

INSTRUCTIONS FOR USE:

• Mix tube vigorously for at least 5 secs.
• Process according to manufacturer’s instructions for sample to result assays.
• Extract nucleic acid prior to use in downstream assays that are not sample to result.

LIMITATION:

• FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES
• Quality control materials should be used in accordance with local, state, federal, and accreditation requirements.
• This product is not intended to replace the manufacturer’s controls provided with the assay.

EXPECTED RESULTS:

• Each laboratory must evaluate the product and establish their own acceptance criteria.
• Virus information and target level listed in table below.

TABLE 1: PANEL MEMBERS

SARS-CoV-2  Panel Member  Isolate  Target Concentration 
Lineage B.1.1.7 Alpha Variant  England/204820464/ 20201  50000 copies/mL5 
Lineage B.1.351 Beta Variant  South Africa/KRISP-K005325/2020
Lineage P.1 Gamma Variant  Japan/TY7-503/2021
Lineage B.1.617.2 Delta Variant  USA/PHC658/20214 

 

 

 

 

 

 

1 This reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/England/204820464/2020, NR-54000, contributed by Bassam Hallis.

2 This reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/South Africa/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de Oliveira.

3 This reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/Japan/TY7-503/2021 (Brazil P.1), NR-54982, contributed by National Institute of Infectious Diseases.

4 This reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/USA/PHC658/2021 (Lineage B.1.617.2; Delta Variant), NR-55611, contributed by Dr. Richard Webby and Dr. Anami Patel.

5 Quantitation based on in-house RT- PCR assay targeting N generegion. Quantitation standard assigned copies/mL by dPCR

 

View AllClose